WARNINGS AND PRECAUTIONS Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported
Injection therapies have the most consistent trial timelines for expected results
Common injection mistakes include injecting too quickly (which causes discomfort), reusing needles (which dulls the tip and introduces bacteria), and applying heat or massage immediately after injection (which accelerates drug absorption unpredictably)
Postgr Med
Medicare plans should list the cardiovascular indication criteria specifically
Development timeline : Survodutide Phase 3 results are expected sooner (H1 2026 for obesity), potentially reaching market before retatrutide